Compare

Surrozen Inc./$SRZN

1D1W1M3M6MYTD1Y5YMAX

About Surrozen Inc.

Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-8141(for wet AMD, DME), SZN-413( For retinopathies) and SZN-8143 (for wet AMD, DME, UME).
Ticker
$SRZN
Sector
Health
Primary listing
NASDAQ
Employees
44
Headquarters
South San Francisco, United States
Website
www.surrozen.com

Surrozen Inc. Metrics

BasicAdvanced
$542M
-
-$32.19
0.56
-

What the Analysts think about Surrozen Inc.

Analyst ratings (Buy, Hold, Sell) for Surrozen Inc. stock.
Analyst projections of the future price of Surrozen Inc. stock.

Bulls say / Bears say

The FDA has cleared SZN-8141 to enter clinical testing for diabetic macular oedema. Its trial will test a dual Wnt-activation and VEGF-blocking approach, with initial data expected in the second half of 2027. (Surrozen)
Boehringer Ingelheim has advanced licensed candidate SZN-413 into a Phase 1 study and is responsible for its further development costs. If the programme succeeds, Surrozen could receive milestone payments and royalties, although the parties disagree over some payment terms. (SEC)
The recently completed $95.1 million financing is expected to fund the DUET study and initial clinical work on SZN-8143, extending Surrozen’s stated cash runway into 2029. That gives the company time to reach several clinical milestones without an immediate need to raise more capital, based on its current plan. (Surrozen)
SZN-8141 has not yet produced patient data, and the first results are not expected until the second half of 2027. The early-stage study is designed to assess safety and look for signs of activity, so its ability to deliver meaningful benefit remains unproven. (Surrozen)
Boehringer Ingelheim says it has grounds to reduce future SZN-413 milestone and royalty payments, while Surrozen says that interpretation is without merit. The disagreement creates uncertainty around the value Surrozen may receive even if the partnered programme advances. (SEC)
The new financing brings substantial potential dilution: after the closing, Surrozen reported 17.8 million common shares, 3.8 million shares issuable through pre-funded warrants and 9.1 million shares issuable through outstanding warrants. Exercise of those warrants could increase the share count and dilute existing holders. (Surrozen)
Data summarised monthly by Lightyear AI. Last updated on 23 Oct 2026.

Surrozen Inc. Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

Surrozen Inc. Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Surrozen Inc. News

AllArticlesVideos

Surrozen Gains Momentum as FDA Submission Opens Path for Lead Therapy

Benzinga1 month ago

Funds containing Surrozen Inc.

Funds
Fund name
Fund size
$SRZN weighting
SPDR Russell 2000 US Small Cap€R2US
$5.3B0.00%
SPDR Russell 2000 US Small Cap£R2SC
$5.3B0.00%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.